
<!DOCTYPE html>
<html lang="zh-TW">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>腎臟學研究週報 - 2026年02月16日</title>
    <style>
        body {
            font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, 'Helvetica Neue', Arial, sans-serif;
            line-height: 1.6;
            color: #333;
            max-width: 800px;
            margin: 0 auto;
            padding: 20px;
            background-color: #f5f5f5;
        }
        .container {
            background-color: #ffffff;
            border-radius: 10px;
            padding: 30px;
            box-shadow: 0 2px 10px rgba(0,0,0,0.1);
        }
        .header {
            text-align: center;
            border-bottom: 3px solid #1E3A5F;
            padding-bottom: 20px;
            margin-bottom: 30px;
        }
        .header h1 {
            color: #1E3A5F;
            margin: 0;
            font-size: 28px;
        }
        .header p {
            color: #666;
            margin: 10px 0 0 0;
        }
        .metrics {
            display: flex;
            justify-content: space-around;
            flex-wrap: wrap;
            margin: 20px 0;
            padding: 20px;
            background-color: #f8f9fa;
            border-radius: 8px;
        }
        .metric {
            text-align: center;
            padding: 10px 20px;
        }
        .metric-value {
            font-size: 36px;
            font-weight: bold;
            color: #1E3A5F;
        }
        .metric-label {
            font-size: 14px;
            color: #666;
        }
        .section {
            margin: 30px 0;
        }
        .section h2 {
            color: #1E3A5F;
            border-left: 4px solid #1E3A5F;
            padding-left: 15px;
            margin-bottom: 15px;
        }
        .finding {
            background-color: #e8f4ea;
            border-left: 4px solid #28a745;
            padding: 10px 15px;
            margin: 10px 0;
            border-radius: 0 5px 5px 0;
        }
        .article {
            border: 1px solid #e0e0e0;
            border-radius: 8px;
            padding: 15px;
            margin: 15px 0;
            background-color: #fafafa;
        }
        .article-title {
            font-weight: bold;
            color: #1E3A5F;
            margin-bottom: 8px;
        }
        .article-meta {
            font-size: 13px;
            color: #666;
        }
        .high-impact {
            display: inline-block;
            background-color: #FFD700;
            color: #333;
            padding: 2px 8px;
            border-radius: 4px;
            font-size: 11px;
            font-weight: bold;
            margin-left: 10px;
        }
        .trend-tag {
            display: inline-block;
            background-color: #e3f2fd;
            color: #1565c0;
            padding: 3px 10px;
            border-radius: 15px;
            font-size: 12px;
            margin: 3px;
        }
        .idea {
            background-color: #fff3e0;
            border-left: 4px solid #ff9800;
            padding: 15px;
            margin: 15px 0;
            border-radius: 0 5px 5px 0;
        }
        .idea-type {
            font-weight: bold;
            color: #e65100;
            margin-bottom: 5px;
        }
        .pico-box {
            background-color: #f0f7ff;
            border: 1px solid #b3d4fc;
            border-radius: 8px;
            padding: 12px;
            margin: 10px 0;
        }
        .pico-title {
            font-weight: bold;
            color: #1565c0;
            margin-bottom: 8px;
            font-size: 14px;
        }
        .pico-item {
            margin: 6px 0;
            font-size: 13px;
            line-height: 1.5;
        }
        .pico-label {
            display: inline-block;
            background-color: #1565c0;
            color: white;
            padding: 2px 8px;
            border-radius: 4px;
            font-weight: bold;
            font-size: 11px;
            margin-right: 8px;
            min-width: 80px;
            text-align: center;
        }
        .chinese-summary {
            background-color: #fff8e1;
            border-left: 4px solid #ffc107;
            padding: 12px 15px;
            margin: 10px 0;
            border-radius: 0 8px 8px 0;
            font-size: 13px;
            line-height: 1.8;
        }
        .chinese-summary-title {
            font-weight: bold;
            color: #f57c00;
            margin-bottom: 8px;
        }
        .summary-section {
            margin: 8px 0;
        }
        .summary-label {
            color: #e65100;
            font-weight: bold;
        }
        .footer {
            text-align: center;
            margin-top: 30px;
            padding-top: 20px;
            border-top: 1px solid #e0e0e0;
            color: #666;
            font-size: 12px;
        }
        a {
            color: #1565c0;
            text-decoration: none;
        }
        a:hover {
            text-decoration: underline;
        }
        @media (max-width: 600px) {
            .metrics {
                flex-direction: column;
            }
            .metric {
                margin: 10px 0;
            }
        }
    </style>
</head>
<body>
    <div class="container">
        <div class="header">
            <h1>腎臟學研究週報</h1>
            <p>2026年02月16日 | 自動追蹤最新高品質腎臟學臨床研究</p>
        </div>

        <!-- 關鍵指標 -->
        <div class="metrics">
            <div class="metric">
                <div class="metric-value">17</div>
                <div class="metric-label">總文章數</div>
            </div>
            <div class="metric">
                <div class="metric-value">1</div>
                <div class="metric-label">高影響力期刊</div>
            </div>
            <div class="metric">
                <div class="metric-value">1</div>
                <div class="metric-label">兒童腎臟學</div>
            </div>
            <div class="metric">
                <div class="metric-value">16</div>
                <div class="metric-label">成人腎臟學</div>
            </div>
        </div>

        <!-- 主要發現 -->
        <div class="section">
            <h2>本週重點發現</h2>
            <div class="finding">本週熱門研究主題: mortality (6篇), proteinuria (4篇), hospitalization (4篇)</div>
            <div class="finding">高影響力期刊發表 1 篇，包括: BMJ open</div>
            <div class="finding">高品質證據: 3 篇 RCT, 0 篇統合分析</div>

        </div>

        <!-- 熱門研究主題 -->
        <div class="section">
            <h2>熱門研究主題</h2>
            <div>
                <span class="trend-tag">mortality (6)</span>
                <span class="trend-tag">proteinuria (4)</span>
                <span class="trend-tag">hospitalization (4)</span>
                <span class="trend-tag">cardiovascular (4)</span>
                <span class="trend-tag">heart failure (3)</span>
                <span class="trend-tag">ESKD (2)</span>
                <span class="trend-tag">biomarker (2)</span>

            </div>
        </div>

        <!-- 重點文章 -->
        <div class="section">
            <h2>重點文章</h2>

            <div class="article">
                <div class="article-title">
                    Multicentre, retrospective observational study on risk factors of major cardiovascular adverse events in patients with chronic kidney disease in Taiwan.<span class="high-impact">高影響力期刊</span>
                </div>
                <div class="article-meta">
                    BMJ open | 研究 | 2026 Feb 15
                    <br><a href="https://pubmed.ncbi.nlm.nih.gov/41692518/" target="_blank">在 PubMed 查看</a>
                </div>
                <div class="pico-box"><div class="pico-title">PICO 格式分析</div><div class="pico-item"><span class="pico-label">P 族群</span>chronic kidney disease in Taiwan</div><div class="pico-item"><span class="pico-label">C 對照</span>the non-ESKD group</div><div class="pico-item"><span class="pico-label">O 結果</span>the incidence of MACE during follow-up</div></div>
                
                <div class="chinese-summary">
                    <div class="chinese-summary-title">中文摘要整理</div>
                    <div class="summary-section"><span class='summary-label'>研究目的</span> 本世代研究旨在探討To assess the incidence and risk of major adverse cardiovascular events (MACE) in patients with different stages of chronic kidney disease (CKD) and end-stage kidney disease (ESKD) in Taiwan.</div><div class='summary-section'><span class='summary-label'>主要結果</span> MACE occurred in 49.8% of patients with CKD and 64.1% of those with ESKD. After adjustment for covariates, the ESKD group had a significantly higher risk of MACE (HR=1.52; 95% CI 1.08 to 2.16) compared with the non-ESKD group. Relative to stage 3a, the adjusted HRs for MACE were 1.13 (95% CI 0.</div><div class='summary-section'><span class='summary-label'>結論</span> Based on a multicentre cohort from Taiwan, our findings provide insights into the prognosis of patients with CKD across disease stages and highlight the importance of targeted interventions and integrated care to improve cardiovascular outcomes.</div>
                </div>
            </div>

            <div class="article">
                <div class="article-title">
                    Real-world comparison of cabozantinib and sunitinib in advanced non-clear cell renal cell carcinoma: A multicenter study by the Turkish Oncology Group.
                </div>
                <div class="article-meta">
                    International journal of cancer | 研究 | 2026 Feb 15
                    <br><a href="https://pubmed.ncbi.nlm.nih.gov/40968962/" target="_blank">在 PubMed 查看</a>
                </div>
                <div class="pico-box"><div class="pico-title">PICO 格式分析</div><div class="pico-item"><span class="pico-label">P 族群</span>advanced or metastatic nccRCC treated with first-line cabozantinib or sunitinib between 2015 and 2025</div><div class="pico-item"><span class="pico-label">I 介入</span>first-line cabozantinib or sunitinib between 2015 and 2025</div><div class="pico-item"><span class="pico-label">C 對照</span>sunitinib (9</div><div class="pico-item"><span class="pico-label">O 結果</span>longer median progression-free survival (PFS) compared to sunitinib (9</div></div>
                
                <div class="chinese-summary">
                    <div class="chinese-summary-title">中文摘要整理</div>
                    <div class="summary-section"><span class='summary-label'>研究目的</span> 本研究旨在探討response rate (ORR) was higher with cabozantinib (38.6% vs. 26.3%; p = .052). Multivariate analyses identified ECOG performance status ≥2, IMDC risk category, sarcomatoid differentiation, and chromophobe histology as independent prognostic factors for OS.</div><div class='summary-section'><span class='summary-label'>主要結果</span> suggest that cabozantinib may offer improved disease control over sunitinib in this diverse patient population and provide valuable real-world insights for therapeutic decision-making in the absence of prospective randomized data.</div>
                </div>
            </div>

            <div class="article">
                <div class="article-title">
                    Early glucagon-like peptide-1 receptor agonist use after myocardial infarction in patients with type 2 diabetes.
                </div>
                <div class="article-meta">
                    International journal of cardiology | 研究 | 2026 Feb 15
                    <br><a href="https://pubmed.ncbi.nlm.nih.gov/41297711/" target="_blank">在 PubMed 查看</a>
                </div>
                <div class="pico-box"><div class="pico-title">PICO 格式分析</div><div class="pico-item"><span class="pico-label">P 族群</span>type 2 diabetes</div><div class="pico-item"><span class="pico-label">C 對照</span>307</div><div class="pico-item"><span class="pico-label">O 結果</span>recurrent coronary events, and secondary outcomes included all-cause mortality and hospitalizations, heart failure (HF) hospitalizations, acute kidney injury (AKI), and cardiac arrest</div></div>
                
                <div class="chinese-summary">
                    <div class="chinese-summary-title">中文摘要整理</div>
                    <div class="summary-section"><span class='summary-label'>研究目的</span> 本世代研究旨在探討Acute myocardial infarction (AMI) is among the leading causes of mortality in patients with type 2 diabetes (T2DM). This study evaluated whether initiation of glucagon-like peptide-1 receptor agonists (GLP1RAs) post-AMI improves cardiovascular outcomes in this population.</div><div class='summary-section'><span class='summary-label'>研究方法</span> This retrospective cohort study used the TriNetX Research Network to identify adult patients with T2DM who experienced an AMI between January 1, 2017, and December 31, 2023. Patients were included if they initiated tirzepatide or semaglutide within 14 days post-AMI.</div><div class='summary-section'><span class='summary-label'>主要結果</span> 5338 patients were included in each cohort. Mean follow-up was 327.7 days (GLP1RA group) vs. 307.9 days (non-GLP1RA group). GLP1RA use did not significantly reduce recurrent coronary events (3.7 % vs 3.8 %; HR 0.913, 95 % CI 0.750-1.111).</div><div class='summary-section'><span class='summary-label'>結論</span> GLP1RA initiation in patients with T2DM post-AMI was not associated with a reduction in recurrent coronary events, but was linked to improvements in other cardiovascular outcomes, suggesting a potential role for GLP1RAs as part of a secondary prevention strategy.</div>
                </div>
            </div>

            <div class="article">
                <div class="article-title">
                    Two-year Follow-up of IgA Nephropathy Patients Who Developed Gross Hematuria Following COVID-19 Vaccination: A Case Series and Literature Review.
                </div>
                <div class="article-meta">
                    Internal medicine (Tokyo, Japan) | 系統性回顧 | 2026 Feb 15
                    <br><a href="https://pubmed.ncbi.nlm.nih.gov/40707219/" target="_blank">在 PubMed 查看</a>
                </div>
                <div class="pico-box"><div class="pico-title">PICO 格式分析</div><div class="pico-item"><span class="pico-label">P 族群</span>Developed Gross Hematuria Following COVID-19 Vaccination: A Case Series and Literature Review</div><div class="pico-item"><span class="pico-label">O 結果</span>the patients' baseline characteristics</div></div>
                
                <div class="chinese-summary">
                    <div class="chinese-summary-title">中文摘要整理</div>
                    <div class="summary-section"><span class='summary-label'>研究目的</span> 本系統性回顧旨在探討Recent reports have shown that patients with immunoglobulin A nephropathy (IgAN) develop gross hematuria after COVID-19 vaccination. However, the two-year prognosis remains uncertain.</div><div class='summary-section'><span class='summary-label'>研究方法</span> We conducted a retrospective review of 301 patients with IgAN at our institution to identify those who developed gross hematuria after COVID-19 vaccination.</div><div class='summary-section'><span class='summary-label'>主要結果</span> Gross hematuria was observed in eight patients after vaccination. Their mean age was 42.9 years, and 87.5% were women. All patients relapsed or did not achieve clinical remission prior to vaccination. The median time to gross hematuria onset was 1.6 days, resolving within 3 days.</div><div class='summary-section'><span class='summary-label'>結論</span> We revealed the extended prognosis of gross hematuria in patients with IgAN following COVID-19 vaccination. With appropriate follow-up, temporary renal deterioration improved within six months and remained stable for two years.</div>
                </div>
            </div>

            <div class="article">
                <div class="article-title">
                    Efficacy and safety of flexible and navigable suction ureteral access sheath combined with flexible ureteroscopic lithotripsy versus flexible ureteroscopic lithotripsy alone for infected upper urinary tract stones: a retrospective cohort study.
                </div>
                <div class="article-meta">
                    World journal of urology | 研究 | 2026 Feb 14
                    <br><a href="https://pubmed.ncbi.nlm.nih.gov/41689658/" target="_blank">在 PubMed 查看</a>
                </div>
                <div class="pico-box"><div class="pico-title">PICO 格式分析</div><div class="pico-item"><span class="pico-label">P 族群</span>upper urinary tract infectious stones (confirmed as struvite or carbonate apatite by postoperative stone composition analysis) who underwent surgery at the First Affiliated Hospital of Xiamen Universi</div><div class="pico-item"><span class="pico-label">I 介入</span>of upper urinary tract infectious stones</div><div class="pico-item"><span class="pico-label">C 對照</span>flexible ureteroscopic lithotripsy alone for infected upper urinary tract stones: a retrospective cohort study</div><div class="pico-item"><span class="pico-label">O 結果</span>higher immediate stone-free rate (53</div></div>
                
                <div class="chinese-summary">
                    <div class="chinese-summary-title">中文摘要整理</div>
                    <div class="summary-section"><span class='summary-label'>研究目的</span> 本世代研究旨在探討To compare the efficacy and safety of flexible negative-pressure ureteral access sheath combined with flexible ureteroscopic lithotripsy (FURL) versus FURL alone in the treatment of upper urinary tract infectious stones.</div><div class='summary-section'><span class='summary-label'>研究方法</span> This retrospective cohort study included 91 patients with upper urinary tract infectious stones (confirmed as struvite or carbonate apatite by postoperative stone composition analysis) who underwent surgery at the First Affiliated Hospital of Xiamen University between January 2023 and January 2025.</div><div class='summary-section'><span class='summary-label'>主要結果</span> Compared to the FURL alone group, the FANS-UAS group had a lower proportion of struvite stones (73.33% vs. 93.55%, P < 0.05) and a lower rate of intraoperative stone basket usage (66.67% vs. 100%, P < 0.05).</div><div class='summary-section'><span class='summary-label'>結論</span> The combination of FANS-UAS and FURL is a safe and effective method for treating upper urinary tract infectious stones. Its advantages include a higher immediate stone-free rate, lower hospitalization costs, reduced need for postoperative adjuvant therapy, a lower incidence of sepsis, and faster pos...</div>
                </div>
            </div>

        </div>

        <!-- 研究想法 -->
        <div class="section">
            <h2>研究想法建議</h2>

            <div class="idea">
                <div class="idea-type">[熱門主題延伸] mortality</div>
                <p>目前 'mortality' 是研究熱點 (6 篇相關文章)，可考慮：<br>1. 在本地族群中驗證相關發現<br>2. 結合其他熱門主題進行交叉研究<br>3. 針對特定亞群進行深入分析</p>
                <p><strong>建議研究類型:</strong> 觀察性研究 / 回顧性分析</p>
            </div>

            <div class="idea">
                <div class="idea-type">[熱門主題延伸] proteinuria</div>
                <p>目前 'proteinuria' 是研究熱點 (4 篇相關文章)，可考慮：<br>1. 在本地族群中驗證相關發現<br>2. 結合其他熱門主題進行交叉研究<br>3. 針對特定亞群進行深入分析</p>
                <p><strong>建議研究類型:</strong> 觀察性研究 / 回顧性分析</p>
            </div>

            <div class="idea">
                <div class="idea-type">[熱門主題延伸] hospitalization</div>
                <p>目前 'hospitalization' 是研究熱點 (4 篇相關文章)，可考慮：<br>1. 在本地族群中驗證相關發現<br>2. 結合其他熱門主題進行交叉研究<br>3. 針對特定亞群進行深入分析</p>
                <p><strong>建議研究類型:</strong> 觀察性研究 / 回顧性分析</p>
            </div>

        </div>

        <!-- 頁尾 -->
        <div class="footer">
            <p>此報告由 PubMed 腎臟學研究週報系統自動生成</p>
            <p>報告時間: 2026年02月16日</p>
        </div>
    </div>
</body>
</html>
